Several studies report inhibiting the tyrosine kinase activity of P210BCRABL1 reduces CXCR4 protein levels which might favor release of CML LSCs from the bone marrow microenvironment into the blood. Here, CXCR4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.